Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$25.26
-11.3%
$25.85
$16.54
$28.67
$374.56M0.7478,387 shs189,719 shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.23
+0.8%
$1.16
$0.98
$1.89
$38.45M-0.6562,667 shs38,166 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$76.00
+1.3%
$66.67
$44.27
$76.24
$1.71B0.88122,788 shs127,948 shs
SI-BONE, Inc. stock logo
SIBN
SI-BONE
$15.54
+3.6%
$15.74
$13.96
$29.51
$618.06M1.24436,564 shs547,212 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$32.32
+2.3%
$28.58
$16.79
$39.41
$460.88M1.0463,059 shs51,108 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-11.28%-8.45%-2.43%+5.12%0.00%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
+0.82%+2.50%-3.15%+3.36%-6.46%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+1.33%+13.82%+13.50%+23.62%+16.21%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
+3.60%+6.37%-4.90%-26.07%-32.20%
Surmodics, Inc. stock logo
SRDX
Surmodics
+2.31%-6.45%+16.47%-1.22%+58.63%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.7537 of 5 stars
1.31.00.03.63.11.71.9
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
3.2385 of 5 stars
3.04.00.04.40.00.00.6
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.4748 of 5 stars
1.42.03.30.02.53.31.9
SI-BONE, Inc. stock logo
SIBN
SI-BONE
4.288 of 5 stars
4.51.00.03.32.42.50.6
Surmodics, Inc. stock logo
SRDX
Surmodics
4.34 of 5 stars
3.52.00.03.43.01.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5016.79% Upside
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50103.25% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.71
Moderate Buy$73.83-2.85% Downside
SI-BONE, Inc. stock logo
SIBN
SI-BONE
3.00
Buy$27.2975.58% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$57.0076.36% Upside

Current Analyst Ratings

Latest SRDX, SIBN, LMAT, ANIK, and CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00 ➝ $37.00
5/7/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$32.00
5/7/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $25.00
5/7/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
5/3/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $77.00
5/3/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$69.00 ➝ $79.00
5/2/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$71.00 ➝ $71.00
5/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $43.00
4/26/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$59.00 ➝ $75.00
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
4/3/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.25$4.50 per share5.61$14.50 per share1.74
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.65N/AN/A$2.81 per share0.44
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$199.89M8.53$1.83 per share41.56$13.38 per share5.68
SI-BONE, Inc. stock logo
SIBN
SI-BONE
$144.05M4.45N/AN/A$4.18 per share3.72
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M3.48$0.78 per share41.43$8.48 per share3.81

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.65N/A18.712.46-49.60%-2.10%-1.71%8/13/2024 (Estimated)
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%N/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.5150.3341.082.9916.99%11.57%10.02%8/6/2024 (Estimated)
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$43.34M-$1.09N/AN/AN/A-31.20%-28.22%-20.53%8/5/2024 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.9534.02N/AN/A9.44%13.30%8.63%8/7/2024 (Estimated)

Latest SRDX, SIBN, LMAT, ANIK, and CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.39$0.44+$0.05$0.44$51.50 million$53.48 million    
5/1/2024Q2 2024
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.36$0.07+$0.43$0.12$28.79 million$31.96 million    
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
2/27/2024Q4 2023
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.36$0.38+$0.02$0.38$49.01 million$48.90 million    
2/26/2024Q4 2023
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$0.29-$0.27+$0.02-$0.27$38.60 million$38.86 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.640.84%+13.80%42.38%13 Years
SI-BONE, Inc. stock logo
SIBN
SI-BONE
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Latest SRDX, SIBN, LMAT, ANIK, and CODX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.86%5/15/20245/16/20245/30/2024
2/21/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.9%3/13/20243/14/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.26
3.76
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
7.57
5.31
SI-BONE, Inc. stock logo
SIBN
SI-BONE
0.21
9.01
8.15
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.39
3.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
98.11%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
10.79%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
5.40%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.83 million13.96 millionOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
61422.45 million20.02 millionOptionable
SI-BONE, Inc. stock logo
SIBN
SI-BONE
34441.20 million38.98 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.26 million12.99 millionOptionable

SRDX, SIBN, LMAT, ANIK, and CODX Headlines

SourceHeadline
Surmodics (NASDAQ:SRDX) Receives Outperform Rating from Barrington ResearchSurmodics (NASDAQ:SRDX) Receives Outperform Rating from Barrington Research
americanbankingnews.com - May 6 at 5:38 AM
Q3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by AnalystQ3 2025 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Analyst
americanbankingnews.com - May 6 at 3:50 AM
Surmodics, Inc. Just Beat Earnings Expectations: Heres What Analysts Think Will Happen NextSurmodics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
finance.yahoo.com - May 4 at 11:04 AM
Surmodics (SRDX) Q2 Earnings Top Estimates, 24 View UpSurmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
zacks.com - May 3 at 2:16 PM
Surmodics (NASDAQ:SRDX) Price Target Cut to $43.00Surmodics (NASDAQ:SRDX) Price Target Cut to $43.00
americanbankingnews.com - May 3 at 5:18 AM
Surmodics (NASDAQ:SRDX) Rating Reiterated by Barrington ResearchSurmodics (NASDAQ:SRDX) Rating Reiterated by Barrington Research
marketbeat.com - May 2 at 3:39 PM
Surmodics (NASDAQ:SRDX) Releases  Earnings Results, Beats Expectations By $0.43 EPSSurmodics (NASDAQ:SRDX) Releases Earnings Results, Beats Expectations By $0.43 EPS
marketbeat.com - May 2 at 2:16 PM
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and SurModics (SRDX)
markets.businessinsider.com - May 2 at 12:58 PM
Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...Surmodics Inc (SRDX) Q2 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
finance.yahoo.com - May 2 at 7:36 AM
Surmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo FinanceSurmodics, Inc. (SRDX) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - May 1 at 9:25 PM
SurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating ReaffirmedSurModics Outperforms with Raised Guidance and Strong Product Momentum: Buy Rating Reaffirmed
markets.businessinsider.com - May 1 at 9:25 PM
Surmodics (NASDAQ:SRDX) PT Lowered to $43.00Surmodics (NASDAQ:SRDX) PT Lowered to $43.00
marketbeat.com - May 1 at 3:06 PM
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024
investorplace.com - May 1 at 1:02 PM
Surmodics (NASDAQ:SRDX) Issues FY 2024 Earnings GuidanceSurmodics (NASDAQ:SRDX) Issues FY 2024 Earnings Guidance
marketbeat.com - May 1 at 10:57 AM
SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesSurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com - May 1 at 10:35 AM
SurModics (SRDX) Q2 Earnings and Revenues Top EstimatesSurModics (SRDX) Q2 Earnings and Revenues Top Estimates
zacks.com - May 1 at 9:31 AM
SurModics: Fiscal Q2 Earnings SnapshotSurModics: Fiscal Q2 Earnings Snapshot
timesunion.com - May 1 at 9:28 AM
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceSurmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
businesswire.com - May 1 at 7:00 AM
SurModics earnings: heres what Wall Street expectsSurModics earnings: here's what Wall Street expects
markets.businessinsider.com - April 30 at 1:24 PM
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
finance.yahoo.com - April 30 at 1:24 PM
Surmodics (SRDX) Set to Announce Quarterly Earnings on WednesdaySurmodics (SRDX) Set to Announce Quarterly Earnings on Wednesday
marketbeat.com - April 24 at 6:45 AM
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
businesswire.com - April 19 at 7:00 AM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
LeMaitre Vascular logo

LeMaitre Vascular

NASDAQ:LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
SI-BONE logo

SI-BONE

NASDAQ:SIBN
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.